Mir Lim

Current hematology/oncology fellow @MDAndersonNews | Former resident @UTSWInternalMed | Alum @BUMedicine

[Eric K. Singhi, MD @lungoncdoc]

Thrilled to congratulate everyone on Match Day, especially the newly matched @MDAndersonNews Hematology & Medical Oncology Fellowship Class of 2029! #EndCancer

[Kai-li Liang @KaiLiangMD]

What an incredible week at the ASCO/AACR Methods in Clinical Cancer Research Workshop! Grateful and inspired by all of the amazing fellows and mentors @ASCO @AACR #vailworkshop #PDG6 #colorectalcancer #CRC @sepideh_gholami @manjuggm @YoussefBouferra @MirLimMD @Guv_onc

[Diane Bodurka @DianeBodurka]

Congratulations to the @MDAndersonNews trainees who received 2025 @ConquerCancerFd Young Investigator and Merit Awards for their contributions to cancer research! Extremely grateful for your hard work and commitment to our mission to #EndCancer. So well-deserved!

[Matteo Lambertini, MD PhD @matteolambe]

Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues
@OncoAlert @AnnPartridgeMD @oncofertility
Link:
https://t.co/ZBvawDBCzW

[Kelsey Pan, MD, MPH @KelseyPanMD]

Grateful for the opportunity to work with the incredible @VanMorrisMD on this phase I/II trial of encorafenib, cetuximab and nivolumab in pts with BRAF V600E mutated mCRC who progressed on prior treatment with BRAF + EGFR targeted tx.
- While the addition of Nivo did not seem to overcome resistance after progression on prior E+C, there remains a role of E+C+N in the BRAF tx naive population

[Oncology Brothers @OncBrothers]

6. #BREAKWATER: Ph 3, Enco + Cetux + mFOLFOX vs SoC in BRAFV600E mCRC

- ORR 61% vs 40%
- Interim OS at 12mos 79.5% vs 66%
- Gr≥3 AEs: 37.7% vs 34.6%
- New SoC for BRAFV600E

7/8

[Pashtoon Kasi MD, MS @pashtoonkasi]

Here’s the @TheLancet publication! 📝

#GI25 @OncoAlert

https://t.co/Su04lwsCjw

[Oncology Brothers @OncBrothers]

#GI25 highlights #CommunityOnc:

1. #SCIENCE: Adv Eso SCC

2. #ESOPEC publication (Eso/GEJ/Ga)

3. Chemo in resectable Panc Ca

4. #StarterNET: GEP-NET

5. #CM8HW: dMMR/MSI-H mCRC

6. #BREAKWATER: BRAFV600E mCRC

7. ctDNA: #BESPOKE + SWOG80702

#OncTwitter #gism @ASCO

1/8

[Shaalan Beg MD MBA FASCO @ShaalanBeg]

Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic?

Pan-RAS inhibitor shows early/deep molecular response (and 36% response rate) for G12X mutated pancreatic cancer.
(Significant AEs: rash, diarrhea, nausea, vomiting)

https://t.co/34qqj8oqGV

[Nicholas Hornstein @GIMedOnc]

#GI25

BREAKWATER

@skopetz changing the paradigm yet again! The true master of BRAF and colorectal targeted therapy.

BRAF+ first line mCRC; n=236 on experimental arm

Enco (BRAF) + Cetux (EGFR)+ FOLFOX

ORR 60% vs 40%!
OS not yet reached!!!

Durable responses and twice as high in experimental arm.

Well tolerated, amazing design to tease out contribution of components.

New standard of care in BRAF+ disease.

@OncoAlert

[Van Morris, MD @VanMorrisMD]

Great data for pts w/ 2+ line met anal cancer for pembrolizumab+ficerafusp alfa (EGFR/TGFb bispecific) -ORR 29% & 41% 12-mo DFS=benefit in liver mets+pCR for exceptional responder ! Exciting signal as combination immuotherapy in anal cancer! @MDAndersonNews #endcancer @BicaraTx

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#GI25 @ASCO #LBA🌟
🚨CM8HW in dMMR #mCRC - the awaited nivo/ipi1 vs nivo PFS 🙌
📌 N=707 across all
lines, 55% 1L, centrally confirmed
📌 PFS HR 0.62, p0.0003 👉3 yr PFS 68% v 51%
📌 ORR 71% vs 58% - PD 10% w/ combo
📌 safely reassuring🤙
➡️nivo/ipi is the new SOC for dMMR mCRC
➡️reserve pembro if ineligle for +CTLA4
…already in NCCN 🇺🇸 ESMO 🇪🇺… 🤞🇨🇦soon!
@OncoAlert @coloncanada @ccranorg

[Ryan Huey, MD, MS @ryanhuey]

Dr. @mgfakih with P2 BOT/BAL study in refractory MSS mCRC w/o liver mets (vs TAS-102 or rego). BOT/BAL 75mg ORR 19% vs 0% SOC. Responses seem durable (data not yet mature). #GI25

[Van Morris, MD @VanMorrisMD]

SOOOO proud of our @MDAndersonNews med onc star fellows @MichaelLaPelusa, @KelseyPanMD, & @MirLimMD presenting their research today on #crcsm day at @ASCO #GI25 ! Future is looking bright with their brilliant minds to #endcancer !

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Superb clinic & research teams working together in #TeamPemm clinic #leusm #BPDCN #MPNSM this month ! @MDAndersonNews #endcancer | L➡️R @doctorpemm Michelle Golez RNTerri Saenz RN Rhona Pinsoy RN
Dr .@MirLimMD Dr Kekejian, Rodney Haltom PA 🙌

[UT Southwestern Internal Medicine @UTSWInternalMed]

Join us in congratulating our resident physicians who are preparing to pursue advanced training through fellowship programs in their chosen specialty! @UTSWIMchief @thomasjwang1 @DinoKazi @UTSWNews
📷

[Eric K. Singhi, MD @lungoncdoc]

Thrilled to welcome the newest class of hematology/medical oncology fellows to @MDAndersonNews!

Excited to work with all of you during training! #EndCancer

[Mark Yarchoan @MarkYarchoan]

IPI+NIVO after prior PD1/L1 in HCC?
➡️Retrospective series, half tx w/ prior BEV/ATEZO (no prior anti-CTLA4)
➡️ORR 22% (7/32)
➡️All responders to late line IPI+NIVO had NONRESPONSE to prior PD1/L1
https://t.co/FRVbqGPD2S

[Mir Lim @MirLimMD]

@sharlenedong @UTSWIMchief @UTSW_IMResRsrch @utswcancer AWW @sharlenedong , so glad to have a friend like you in residency! 🥹😭

[Gaples Institute @GaplesInstitute]

Very happy to be partnering with UT Southwestern Medical Center to provide our #NutritionEducation course to medical students in the ambulatory clerkship program! Welcome to those students who begin their nutrition course today! 🩺🍓
#MedEd #FoodAsMedicine #FoodIsMedicine #MedEd